Fujifilm and BioCryst Lagging In Ebola Race
This article was originally published in PharmAsia News
Executive Summary
While a few pharma firms are ramping up production of their untested Ebola treatments with the prospect of reaping substantial sales, Fujifilm Holdings’ and BioCryst’s drugs are still at the preclinical stage.